The Synmosa Group, guided by our corporate strategy of sustainable development :“organic growth, continuous mergers and acquisitions, and strategic alliances”, has established factories in Hsinchu Hukou, Taichung, and New Taipei City through vertical expansion and horizontal integration. Synmosa optimizes its operations in response to international specifications, and is one of the few pharmaceutical groups in Taiwan that are moving towards “automation, maximization, and specialization.” We use our advantage in niche technology platforms: MDI, sex hormones, nasal sprays, effervescent tablets, and granules for our positioning. We excel in cardiovascular, respiratory, sex hormones, urology, and oncology oriented therapeutic products. Synmosa has special technical platforms that are internationally competitive and have allowed us to lock on to niche market products. Brand drugs and new drugs are now a focal point for the company. The key to our continuous and stable growth is a focus on high threshold special technology and characteristic pharmaceuticals.
Synmosa business has expanded into the international market and our global network includes substantial investment in Taiwan, Hong Kong and China where we have created our own excellent marketing teams and strategic partners. We also have long-term partners in Finland, France, Japan, Australia, Thailand, Singapore, and several other Southeast Asian countries. Our most recent establishment is an office in Vietnam opened specifically to speed up market development in the region. We insist on using the highest standard of pharmaceutical manufacturing technology to improve the quality of people’s lives. Synmosa is doing our part by giving back to society and actively participating in social welfare. We remain committed to our core values “honesty, credibility, reliability, and innovation” to maximize the value we create for society and our shareholders as we move towards our vision of becoming the foremost specialty biopharmaceutical corporation in Asia